The review focuses on the role of amino acid PET in this context, as well as the potential use of PET probes targeting the IDH mutation for response assessment in clinical trials using IDH inhibitors for treating IDH-mutant gliomas [12]. Here, IDH1 is linked to central nervous system cancer.